As there is currently limited research on pediatric ME/CFS, the purpose of the study is to improve our understanding of the symptoms and experiences of youth with ME/CFS by conducting a research survey. Who: The Center for Community Research at DePaul University When: Ongoing What: We would like to invite children/adolescents (ages 5-17) with myalgic
It appears that Cochrane will NOT temporarily remove a review from its database that claims exercise therapy is effective for chronic fatigue syndrome (CFS) and myalgic encephalomyelitis (ME), as a report in Reuters had indicated last week. Instead, Cochrane editors have added an editor’s note (that is all but invisible unless you really go searching for it)
Cochrane has temporarily removed a review from its database that claims exercise therapy is effective for chronic fatigue syndrome (CFS) and myalgic encephalomyelitis (ME). Cochrane is a database of medical reviews and meta-analyses, which medical providers around the world rely on for diagnosing and treating disease. Their review, Exercise Therapy for Chronic Fatigue Syndrome, covers
A week after the recent RCGP Annual Primary Care Conference & Exhibition held in Glasgow on the 4th – 6th October, it seems appropriate to reflect on the impact of the conference on educating GPs about myalgic encephalomyelitis (ME). The RCGP Conference is the must-attend event of the year for GPs and practice team colleagues, showcasing
Researchers at Stanford University have discovered that the brains of patients with ME display abnormalities in the white matter within the right hemisphere. It is crucial to further the research involved with these findings as they may lead to more definitive diagnoses of ME. Who: Dr. Montoya and Dr. Zeineh at the Stanford School of Medicine When: Ongoing What:
Emerge Australia has released a report on the findings of a survey of more than 600 Australians with ME/CFS. The National Survey of the Health and Wellbeing of People with ME/CFS was carried out in conjunction with ASDF Research, and highlights the need for greater understanding of ME/CFS in Australia.
The POTS and Beyond conference held in Salt Lake City this past weekend brought together experts in the field to educate physicians and patients on what is known about autonomic dysfunction. The neurology department of the University of Utah School of Medicine partnered with Dysautonomia International and Granger Medical to create this two-day event. The
This study is interested in ME/CFS patients who would classify themselves in the severe category (mostly bedbound, could be housebound). Dr. Montoya and Dr. Michelle James, a neuroradiologist at Stanford University, aim to investigate the inflammatory process in the brain of ME/CFS patients. They believe that this study could lead to improvements in our understanding of the disease
The InTime Trial aims to assess the effects of the investigational drug, CT38, in terms of its safety and effectiveness in treating ME/CFS. There will be 18 people between 18 and 60 years of age enrolled in this study and participation will last up to approximately 4 months. Who: Dr. Lucinda Bateman, Located in Salt
The Stanford Genome Technology Center will host the Second Annual Community Symposium on the Molecular Basis of ME/CFS, sponsored by the Open Medicine Foundation, at Stanford University on Saturday, Sept. 29. The following researchers will be presenting: Ronald W. Davis, PhD, Maureen Hanson, PhD, Jonas Bergquist, MD, PhD, Wenzhong Xiao, PhD, Alain Moreau, PhD, Ronald G.
